AQR Capital Management’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.6M | Buy |
3,001,521
+1,839,516
| +158% | +$2.24M | ﹤0.01% | 1953 |
|
|
2025
Q4 | $1.14M | Buy |
1,162,005
+30,591
| +3% | +$36.7K | ﹤0.01% | 2472 |
|
|
2025
Q3 | $1.43M | Buy |
1,131,414
+285,181
| +34% | +$307K | ﹤0.01% | 2213 |
|
|
2025
Q2 | $948K | Buy |
846,233
+261,208
| +45% | +$304K | ﹤0.01% | 2235 |
|
|
2025
Q1 | $462K | Buy |
585,025
+437,423
| +296% | +$536K | ﹤0.01% | 2472 |
|
|
2024
Q4 | $244K | Buy |
147,602
+123,518
| +513% | +$311K | ﹤0.01% | 2589 |
|
|
2024
Q3 | $84.3K | Buy |
24,084
+7,624
| +46% | +$29.7K | ﹤0.01% | 2668 |
|
|
2024
Q2 | $54K | Sell |
16,460
-5,638
| -26% | -$24.7K | ﹤0.01% | 2536 |
|
|
2024
Q1 | $162K | Sell |
22,098
-212,960
| -91% | -$1.32M | ﹤0.01% | 2286 |
|
|
2023
Q4 | $879K | Sell |
235,058
-97,853
| -29% | -$231K | ﹤0.01% | 1650 |
|
|
2023
Q3 | $706K | Buy |
+332,911
| New | +$1.1M | ﹤0.01% | 1728 |
|
|
2023
Q2 | – | Sell |
-271,399
| Closed | -$1.55M | – | 2215 |
|
|
2023
Q1 | $1.55M | Buy |
+271,399
| New | +$1.64M | ﹤0.01% | 1359 |
|
|
2022
Q2 | – | Sell |
-15,438
| Closed | -$599K | – | 2216 |
|
|
2022
Q1 | $599K | Sell |
15,438
-11,393
| -42% | -$441K | ﹤0.01% | 1749 |
|
|
2021
Q4 | $1.57M | Sell |
26,831
-9,301
| -26% | -$527K | ﹤0.01% | 1323 |
|
|
2021
Q3 | $2.14M | Sell |
36,132
-1,992
| -5% | -$156K | ﹤0.01% | 1101 |
|
|
2021
Q2 | $3.31M | Buy |
38,124
+4,277
| +13% | +$345K | 0.01% | 969 |
|
|
2021
Q1 | $2.79M | Sell |
33,847
-1,475
| -4% | -$141K | ﹤0.01% | 1034 |
|
|
2020
Q4 | $3.21M | Sell |
35,322
-5,184
| -13% | -$322K | 0.01% | 942 |
|
|
2020
Q3 | $1.62M | Sell |
40,506
-8,979
| -18% | -$314K | ﹤0.01% | 1205 |
|
|
2020
Q2 | $1.7M | Sell |
49,485
-2,994
| -6% | -$89.2K | ﹤0.01% | 1232 |
|
|
2020
Q1 | $1.17M | Buy |
52,479
+33,393
| +175% | +$844K | ﹤0.01% | 1274 |
|
|
2019
Q4 | $374K | Sell |
19,086
-10,493
| -35% | -$167K | ﹤0.01% | 1854 |
|
|
2019
Q3 | $459K | Sell |
29,579
-403
| -1% | -$7.72K | ﹤0.01% | 1783 |
|
|
2019
Q2 | $609K | Sell |
29,982
-3,790
| -11% | -$68.3K | ﹤0.01% | 1669 |
|
|
2019
Q1 | $593K | Sell |
33,772
-5,042
| -13% | -$79.6K | ﹤0.01% | 1745 |
|
|
2018
Q4 | $498K | Sell |
38,814
-8,393
| -18% | -$117K | ﹤0.01% | 1781 |
|
|
2018
Q3 | $769K | Hold |
47,207
| – | – | ﹤0.01% | 1803 |
|
|
2018
Q2 | $535K | Buy |
47,207
+15,170
| +47% | +$167K | ﹤0.01% | 1957 |
|
|
2018
Q1 | $313K | Buy |
+32,037
| New | +$307K | ﹤0.01% | 2038 |
|
Other funds holding FATE
RG
VCM
VPM
JJ
AQR Capital Management's FATE Position: Q1 2026 in Review
AQR Capital Management increased its Fate Therapeutics (FATE) stake by 158% in Q1 2026, buying an estimated $2.24M and bringing the position to 3,001,521 shares worth $3.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1953.
AQR Capital Management first reported a position in FATE in Q1 2018 and has held it in 29 quarters since. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.
- AQR Capital Management held 3,001,521 shares of Fate Therapeutics worth $3.6M as of Q1 2026.
- AQR Capital Management bought 1,839,516 Fate Therapeutics shares in Q1 2026, an estimated $2.24M.
- Fate Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1953 holding.
- AQR Capital Management first reported a position in Fate Therapeutics in Q1 2018 and has held it in 29 quarters since.
- 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.
Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.